That is an interesting legal ploy/happening, but may prove inconsequential to many of world population who have DES. It is a large market potential.
As I have posted elsewhere, my off-label prescription for Amarin's Vascepa, initiated 4/01/2013 , cured my DES within a week of 1st dose. It remains gone today, 4+ years later. Anecdotally, Vascepa has done the same for others. A talk with my wife's Hopkins room-mate, a retired anaethesiologist, this past weekend revealed that Restasis did not work for her when tried for DES.
My cost for Vascepa, originally prescribed off-label for other purposes, is $9 per month. Neither Shire nor AGN will match that cost....and no doubt both will await results of Amarin's R-I phase 3 trial in 2018 with interest. I DO NOT KNOW WHETHER THE 30+ SECONDARY INDICATIONS OF THAT REDUCE-iT TRIAL INCLUDE DES. There is scientific literature supporting the use of EPA, icosapent ethyl, in treating DES. OTC Salmon oil, or other fish oils, never worked for me and DES treatment.
Market Data 
Markets 
AI
